Panacea Biotech surges on winning Rs 170 crore award from UN Agencies

Panacea Biotech Limited has announced that it has bagged an award of Rs 170 crore from U.N. Agencies for the supply of its Easyfive-TT, a fully liquid WHO prequalified wP-based Pentavalent Vaccine (DTwPHepB-Hib).

Pediatric vaccination plays an important role to achieve sustainable development goals set by the United Nations. In particular, it targets to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases, namely, Diphtheria, Tetanus, Pertussis, Hepatitis B, and invasive infections caused by Haemophilus Influenza Type B, which makes it the foundation of paediatric immunization programs across the world.

Easyfive -TT was introduced by Panacea Biotec as the world's first fully liquid wP-based pentavalent vaccine in Indian market in 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries, globally. Easyfive-TT is a ready to use drug without further preparation by healthcare workers, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems.

Panacea Biotec has contributed significantly for children's health and has partnered with WHO, UNICEF, and PAHO in their efforts to maximize coverage of vaccines under the Expanded Program on Immunization (EPI) in developing countries. As a responsible and reliable partner, Panacea Biotec, thus, contributes to the success of the Global Alliance for Vaccines and Immunization (GAVI Alliance) in accelerating the access to these vaccines across the world.

Reacting to this event, the stock of Panacea Biotech surged by 10.9 per cent to Rs 138.90 from its previous close of Rs 125.25.